Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padsevonil adjunctive treatment for drug-resistant focal-onset seizures
2018-002303-33Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of padsevonil in Focal Onset Epilepsy, Focal onset seizure and epilepsy (4 arms), sponsored by UCB. Primary endpoint: 75% responder rate from baseline over the 12-week maintenance period. Started Dec 2018; status: completed.
02
Drugs
padsevonil
03
Conditions
Focal Onset EpilepsyFocal onset seizureepilepsy
Beyond the preview
Go deeper on 2018-002303-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002303-33.